TP53突变不仅深刻影响着慢性淋巴细胞白血病(CLL)的疾病进展轨迹,还直接关联到患者的不良预后,成为评估疾病严重程度与制定个性化治疗策略时不可忽视的重要因素。在备受瞩目的第29届欧洲血液协会年会(EHA 2024)上,来自德国乌尔姆大学第三内科的Consu...
candidate genes in a set of 169 additional CLL patients, we used a combination of PCR amplification and Illumina sequencing in pooled samples, resulting in efficient identification of germline and somatic mutations (Supplementary Information). Sequencing data were aligned to the human reference genome ...
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
参考文献: 1. Escalón MP, Woyach JA, Coombs CC, et al. BRUIN CLL-314: a phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (...
Select a VENCLEXTA® indication. VENCLEXTA is an oral therapy for select AML, CLL and SLL patients. See full safety and Prescribing Information for more details.
Rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV)BOXED WARNINGS and Additional Important Safety Information WARNING: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL ...
To be able to connect with you and share your HIPAA-protected information, tell your care provider to download our @Point of Care Suite App or register online at www.atpointofcare.com. This valuable management tool enables patients with Chronic Lymphocytic Leukemia (CLL) to track and store ...
To be able to connect with you and share your HIPAA-protected information, tell your care provider to download our @Point of Care Suite App or register online at www.atpointofcare.com. This valuable management tool enables patients with Chronic Lymphocytic Leukemia (CLL) to track and store ...
Find info for patients about RITUXAN® (rituximab) medication for RA, NHL, CLL, GPA, MPA, and PV. See full safety and Boxed Warning for more information.
Learn about CALQUENCE® (acalabrutinib), a treatment option for adult patients with previously treated mantle cell lymphoma (R/R MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).